Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of liprotamase in cystic fibrosis-related exocrine pancreatic insufficiency
2016-002851-92Phase 3Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Jul 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of liprotamase in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Long-term safety of liprotamase. Started Jul 2016; status: terminated.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-002851-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002851-92.